中医治未病领域中免疫组库(TCR/BCR)作为一种新型“全息”生物标志物的应用与展望

Application and Prospects of the Immune Repertoire(TCR/BCR)as a Novel"Holographic"Biomarker in the TCM Preventive Treatment

中医“治未病”理论构成了中医药健康管理的主要内容,“治未病”思想为中医药健康管理体系赋予科学内涵,中医药健康管理体系也是“治未病”思想的外在体现,该体系的建立与完善离不开中医“治未病”思想的深度解析。“治未病”思想的深度解析需要从科学意义上深度思考三个关键问题:一是如何客观描述“未病”的生物学基础并阐明“未病”发生机制;二是如何阐释中医“治未病”科学内涵及中药复方的特殊药理效应机制;三是如何构建以中医“治未病”为内核的中医药精准健康管理新模式。本文从监管科学角度出发,首次提出“全息”生物标志物免疫组库(TCR/BCR)可作为新型“全息”生物标志物,用以客观表征中医治未病生物学基础和干预效果的科学评价体系,进而作为新的科学证据解释上述三个关键科学问题。

The theory of“preventive treatment of diseases”in Traditional Chinese Medicine(TCM)constitutes the main content of health management of TCM.The concept of“preventive treatment of diseases”gives scientific connotation to the health management system of TCM.The establishment and improvement of the health management system is in turn inseparable from the in-depth analysis of the"preventive treatment of diseases"in TCM.The in-depth analysis of the idea of“preventive treatment of diseases”requires deep consideration of three key scientific questions:(1)how to objectively describe the biological basis of status of“pre-diseases”and clarify the mechanism;(2)how to interpret the scientific concept of“preventive treatment of diseases”and the specific pharmacological effect mechanism of TCM compound;(3)how to build a new model of precise health management of TCM with“preventive treatment of diseases”as the core.This paper proposes,from the perspective of regulatory science and for the first-time,new tools,methods and standards for the objective characterization of the new“holographic”immune repertoire(TCR/BCR)biomarker as new scientific evidence to address the above three key scientific questions.